Skip to content


  • Original investigation
  • Open Access

Deficiency of mast cells in coronary artery endarterectomy of male patients with type 2 diabetes

  • 1,
  • 2,
  • 2,
  • 2,
  • 2 and
  • 2Email author
Cardiovascular Diabetology201110:40

  • Received: 3 March 2011
  • Accepted: 14 May 2011
  • Published:



Type 2 diabetes is an important risk factor for the development of coronary artery disease (CAD). Focal or diffuse inflammation is often present in the vessels of patients with CAD. Mast cells are frequently present in the plaques as well as in the inflammatory infiltrates in the atherosclerotic vessel wall. In the study we wanted to examine whether there are differences in the morphology, number and distribution of mast cells and in their ability to modify the atherosclerotic process in coronary arteries (CA) in the diabetic vs. the hypertensive population of patients with CAD.


Coronary artery endarterectomy specimens were obtained from patients with diabetes or hypertension as the only risk factor for CAD. The specimens were stained with haematoxylin-eosin and Sulphated Alcian Blue for mast cells and with immunofluorescent methods for fibrinogen-fibrin and IgG deposits in the vessel wall. Both morphological and stereological assessments were conducted for mast cells and mononuclear cell infiltrates.


The histological analysis of the vessel wall of diabetic patients in comparison with hypertensive patients showed a damaged endothelial cells layer and deposits of fibrin-fibrinogen and IgG in the tunica intima and media. The stereological count revealed a diminished numerical density of mast cells and a significantly higher volume density of the mononuclear cells. Mast cells displayed cytoplasmic vacuolization, extracellular extrusion of granule and pyknotic nuclei.


This preliminary study suggests that the impaired mast cells might be the reason for more extensive inflammatory and immunologic atherosclerotic changes in the CA vessel wall of CAD patients with type 2 diabetes.

Trial registration



  • Mast Cell
  • Coronary Artery Disease Patient
  • High Density Lipoprotein
  • Endothelial Cell Layer
  • Mononuclear Cell Infiltrate


Coronary artery disease (CAD) can be macroscopically visible as one or more localized atherosclerotic plaques, or as a diffuse, long, concentric thickness of the vessel wall, which protrudes and obstructs the vessel lumen. These changes alter the structure of the vessel wall, ultimately disrupting normal cardiac function. CAD is defined as a chronic inflammatory disease, and several cytokines and growth factors are involved in the pathogenesis of the disease [16]. Surgical procedures on coronary arteries (endarterectomy) enable the performance of morphologic and morphometric analyses of atherosclerotic changes of the coronary arteries. Important risk factors for the development of CAD are type 2 diabetes and arterial hypertension. Atherosclerosis is now generally accepted as a chronic inflammatory condition and there is also growing evidence of an important role of chronic inflammation in type 2 diabetes [7].

The differences in the content and recruitment [8] of various inflammatory cells [9] and their autocrine and paracrine secretory activities have been reported to influence the fate of the atherosclerotic plaque. Among the inflammatory cells, mast cells are obligatory accompanying elements of the localized and diffuse inflammatory changes in the atherosclerotic vessel wall. In the last few years, several investigations have shown that the largest density of mast cells is located in the atherosclerotic plaque of the vessel wall, both in early and advanced CAD, especially in the shoulder region of unstable plaques [1012]. Mast cells play a crucial role in the inflammatory process [13, 14] via many secretory mediators [15], in the activation of other inflammatory cells (e.g. lymphocytes, T macrophages and foam cells) and in influencing the metabolism and the circulation of HDL and LDL lipoproteins. Proteoglycans and proteases derived from activated mast cells play an important role in the regulation of coagulation and fibrinolysis, processes that are closely connected with the development and complications of the atherosclerotic process. The release of heparin as an anticoagulant substance from the mast cells, which leads to higher endogenous heparin levels and higher levels of IgE, may have the primary role in the protective function of vessel wall endothelial cells and act to reduce the complications of CAD [16]. It was reported that [17] mast cells may influence the course of the atherosclerotic process by releasing cytokines from their secretory granules and by coordinating the transportation of inflammatory cells in the vessel wall.

We hypothesized that the morphology, number, distribution and probably the function of mast cells may differ in CAD patients with type 2 diabetes or arterial hypertension, as the only risk factor. Thus, we examined endarterectomy specimens of CA from CAD patients with diabetes or with arterial hypertension using histological and histomorphometrical analyses (a stereological count with the volume density of the mononuclear infiltrates, and the numeric density of mast cells).


Coronary endarectomy sequesters were obtained during Coronary Artery Bypass Graft Surgery (CABG) at the University Clinic of Cardiovascular Surgery, Novi Sad, Serbia, from 20 patients with CAD. The study was approved by the National Medical Ethics Committee. In 20 patients with CAD CABG surgery was performed due to angina pectoris, whereas endarectomy was performed in those coronary arteries with diffuse stenotic lesions. Twenty consecutive patients with diffuse CAD were enrolled in the study with either type 2 diabetes or arterial hypertension. The exclusion criteria were type 1 diabetes and the presence of both disorders (arterial hypertension and type 2 diabetes). Patients were divided in two groups the group of patients with type 2 diabetes only (N = 10) and the group of patients with arterial hypertension only (N = 10) (Table 1). The diabetic patients had been treated for 9.5 ± 1.716 years, the hypertensive patients for 7.5 ± 1.080 years. After informed consent was obtained from the patients, a detailed interview was made. Patients were classified as having type 2 diabetes according to the current American Diabetes Association criteria for the diagnosis and classification of diabetes [18]. The body mass index (BMI) was calculated as weight in kilograms divided by height in square meters. Total cholesterol, low density lipoproteins (LDL), high density lipoproteins (HDL) and triglycerides were determined by standard biochemical methods. Cigarette smoking was defined as a binary variable.
Table 1

Clinical data about diabetic and hypertensive groups of patients


Diabetic group

Hypertensive group

P value





Age (years)

56.6 ± 7.58

60 ± 6.16


BMI (kg/m2)

28.08 ± 2.44

27.6 ± 3.37


Systolic pressure (mmHg)

126.5 ± 6.26

174.5 ± 17.07

< 0.001

Diastolic pressure (mmHg)

79.5 ± 5.50

113.4 ± 10.80

< 0.001

Glucose level (mmol/l)

7.54 ± 1.61

4.64 ± 0.82

< 0.001

Total cholesterol (mmol/l)

6.52 ± 1.57

5.82 ± 1.56


HDL cholesterol (mmol/l)

1.04 ± 0.04

1.25 ± 0.45


LDL cholesterol (mmol/l)

3.26 ± 1.43

3.85 ± 1.68


Triglycerides (mmol/l)

2.35 ± 0.76

1.78 ± 0.6


Cigarette smoking

2 (20%)

3 (30%)


Endarterectomy specimens were surgically taken from the left anterior descendent coronary artery, the left circumflex coronary artery, or the right coronary artery. The tissue samples were formaldehyde fixed, embedded in paraffin and cut into 5 μm thick serial sections. The standard haematoxylin-eosin staining method for the vessel wall tissue and the Sulphated Alcian Blue method for the demonstration of intracellular or extracellular localization of mast cell granules were used. Immunofluorescent methods were performed to show fibrinogen-fibrin and IgG deposits in the endarterectomy specimens as described previously [19]. The number of mast cells and mononuclear cells were counted in 20 random high power fields (× 400). The numerical density of the mast cells and the volume density of the mononuclear cells infiltrates were calculated using previously described stereologic methods [20, 21]. Histological, immunofluorescent and stereological analyses were performed in step serial sections. Degranulated mast cells were defined as cells with > 50% of cytoplasmic granules extruded extracellular in the vicinity of the cell body (Figure 1). Their presence was noted in 20 random high power fields (× 1000 magnification) [22]. Numerical data are reported as a mean value ± SD. The stereological results for mast cells and mononuclear cells infiltrates for diabetic and non diabetic patients were analyzed with the Student t-test. The P value < 0.05 was considered as statistically significant. A statistical analysis was performed using the Excel program, Microsoft Office 2003.
Figure 1
Figure 1

Degranulated mast cells with picnotic nucleus (bar = 20 μm).


The clinical data of patients with type 2 diabetes and arterial hypertension are shown in Table 1. Patients had no statistically significant difference in BMI, total cholesterol, LDL cholesterol and triglycerides, and in the incidence of cigarette smoking, whereas the difference in the HDL cholesterol level was of borderline significance. Due to different inclusion criteria, they differ in blood pressure and glucose level (Table 1).

Moreover, they did not differ in the frequency of lipid-lowering drugs, beta blockers, ACE inhibitors and antiplatelet drugs.

In diabetic patients, a histological analysis revealed a focal or diffuse mononuclear cells infiltration, the presence of fibrin-fibrinogen and IgG deposits in the tunica intima and tunica media of the endarterectomized coronary vessels. In hypertensive patients, fibrin-fibrinogen as well as IgG deposits were absent, and mononuclear infiltrates were rarely observed. In CAD patients with type 2 diabetes, damaged endothelial cells and large areas of luminal boundaries without endothelium with denuded intimal layers were found. In CAD patients with arterial hypertension only, continuous endothelial cell layers were demonstrated.

The morphological analysis of mast cells showed that the nuclear pyknosis, vacuolization and degranulation of mast cells were more intense in diabetic patients in comparison with hypertensive patients. Morphometric analysis demonstrated a significantly higher volume density (Vv) of mononuclear cells infiltrates in diabetic patients in comparison with hypertensive patients (Figure 2). Moreover, a lower numerical density of mast cells (Nvm) was demonstrated in diabetic patients in comparison with non-diabetic patients with arterial hypertension (Figure 3).
Figure 2
Figure 2

Volume density (Vv) of mononuclear cells infiltrates in diabetics in comparison with hypertensive patients. *P < 0.05.

Figure 3
Figure 3

Numerical density of mast cells (Nvm) in diabetic group in comparison with hypertensive group of patients. * P < 0.05.


In this preliminary study we demonstrated a clear difference in atherosclerotic lesions in CAD patients with type 2 diabetes in comparison with the patients from the hypertensive group. The samples from diabetic patients showed a greater degree of inflammation compared to the samples of hypertensive patients. The fibrin-fibrinogen and IgG deposits, accompanying abundant mononuclear cells infiltrates, and damaged endothelial cells of coronary arteries may indicate that atherosclerosis in diabetic patients constitutes humoral [23] and cellular immune responses [24, 25]. We postulate that normal mast cells play an important role in the protection of the integrity of endothelial cell layers and the vessel wall, probably via their paracrine activity, especially through the release of heparin. It is known that in hyperglycemic conditions heparin may protect cells from injury [26]. In diabetic patients, the nuclear pyknosis, degranulation and vacuolization of the mast cells in the CA indicate that they are damaged. Therefore, their protective role of the vessel wall may be diminished. Their impairment, lower numeric density, nuclear pyknosis, degranulation and vacuolization of the mast cells in diabetic patients might be the reasons for more extensive inflammatory and immunologic atherosclerotic changes observed in diabetic CAD patients in comparison with hypertensive CAD patients. The lower number of impaired mast cells cannot coordinate the normal transportation of mononuclear cells through the vessel wall. Inflammatory cells, fibrin-fibrinogen and IgG deposits accumulate in the vessel wall as atherosclerotic plaques that protrude and occlude vessel lumen. In contrast, in hypertensive CAD patients, the morphology of mast cells was normal and the inflammatory changes were less intense. Fibrin-fibrinogen and IgG deposits accumulations were absent. A diminished numerical density of impaired mast cells and a significantly higher number of mononuclear cells infiltrates in the atherosclerotic plaques of CA vessel wall indicate differential inflammatory processes within the CA vessel wall in diabetic patients vs. hypertensive patients.

A major limitation of this preliminary study is the relatively low number of CAD cases with either type 2 diabetes or arterial hypertension. We are planning to enroll new CAD cases with either type 2 diabetes or arterial hypertension to increase the reliability of the study. However, there are only some patients with CAD suitable for the endarterectomy procedure. Further studies enrolling larger numbers of CAD are needed to confirm our findings.


This preliminary study suggests that the impaired mast cells might be the reason for more extensive inflammatory and immunologic atherosclerotic changes in the CA vessel wall of CAD patients with type 2 diabetes. Moreover, we speculate that mast cells are differently involved in atherosclerotic lesions in CAD patients with type 2 diabetes in comparison with hypertensive patients.



coronary artery disease


coronary arteries


Body mass index


high density lipoprotein


low density lipoprotein


immunoglobulin G


volume density


numerical density of mast cells


standard deviation


Acknowledgements of financial support

This work was supported by the program grants from the Ministry of Higher Education, Science and Technology of Slovenia P3-0019.

Authors’ Affiliations

Department of Internal Medicine, University Medical Centre of Ljubljana, Zaloška 2, 1000 Ljubljana, Slovenia
Medical Faculty, University of Ljubljana, Institute of Histology and Embryology, Korytkova 2, 1000 Ljubljana, Slovenia


  1. Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med. 1999, 14 (340): 115-126.Google Scholar
  2. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R: Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997, 336: 1276-1282. 10.1056/NEJM199705013361802.View ArticlePubMedGoogle Scholar
  3. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005, 352: 1685-1695. 10.1056/NEJMra043430.View ArticlePubMedGoogle Scholar
  4. Kariz S, Milutinovic A, Bregar D, Terzic I, Terzic R, Lovrecic L, Herova M, Hruskovicova H, Peterlin B, Petrovic D, Zorc-Pleskovic R: The interleukin-1 receptor antagonist gene and the inhibitor of kappa B-like protein gene polymorphisms are not associated with myocardial infarction in Slovene population with type 2 diabetes. Coll Antropol. 2007, 31: 503-507.PubMedGoogle Scholar
  5. Kariz S, Grabar D, Krkovic M, Osredkar J, Petrovic D: Polymorphisms in the promoter region of the basic fibroblast growth factor gene are not associated with myocardial infarction in a Slovene population with type 2 diabetes. J Int Med Res. 2009, 37: 1596-1603.View ArticlePubMedGoogle Scholar
  6. Petrovic D, Verhovec R, Globocnik Petrovic M, Osredkar J, Peterlin B: Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology. 2007, 107: 291-295. 10.1159/000099064.View ArticlePubMedGoogle Scholar
  7. Festa A, D'Agostino R, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002, 51: 1131-1137. 10.2337/diabetes.51.4.1131.View ArticlePubMedGoogle Scholar
  8. Eriksson EE: Mechanisms of leukocyte recruitment to atherosclerotic lesions: future prospects. Curr Opin Lipidol. 2004, 15: 553-558. 10.1097/00041433-200410000-00009.View ArticlePubMedGoogle Scholar
  9. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT: Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000, 102: 2180-2184.View ArticlePubMedGoogle Scholar
  10. Marone G, de Crescenzo G, Florio G, Granata F, Dente V, Genovese A: Immunological modulation of human cardiac mast cells. Neurochem Res. 1999, 24 (9): 1195-202. 10.1023/A:1020776807187.View ArticlePubMedGoogle Scholar
  11. Constantinides P: Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation. 1995, 92: 1083.View ArticlePubMedGoogle Scholar
  12. Theoharides TC, Cochrane DE: Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol. 2004, 146: 1-12. 10.1016/j.jneuroim.2003.10.041.View ArticlePubMedGoogle Scholar
  13. Bucova M, Bernadic M, Buckingham T: C-reactive protein, cytokines and inflammation in cardiovascular diseases. Bratisl Lek Listy. 2008, 109: 333-340.PubMedGoogle Scholar
  14. McNeil HP, Adachi R, Stevens RL: Mast cell-restricted tryptases: structure and function in inflammation and pathogen defense. J Biol Chem. 2007, 282: 20785-20789. 10.1074/jbc.R700017200.View ArticlePubMedGoogle Scholar
  15. Abraham SN, St John AL: Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 2010, 10: 440-452. 10.1038/nri2782.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Sinkiewicz W: Endogenous heparin - a protective marker in patient with myocardial infartion. Coron Artery Dis. 2002, 13: 423-426. 10.1097/00019501-200212000-00007.View ArticleGoogle Scholar
  17. Lappalainen H, Laine P, Pentikäinen MO, Sajantila A, Kovanen PT: Mast cells in neovascularized human coronary plaques store and secrete basic fibroblast growth factor, a potent angiogenic mediator. Arterioscler Thromb Vasc Biol. 2004, 24: 1880-1885. 10.1161/01.ATV.0000140820.51174.8d.View ArticlePubMedGoogle Scholar
  18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997, 20: 1183-1197.View ArticleGoogle Scholar
  19. Vukojevic K, Carev D, Sapunar D, Petrovic D, Saraga-Babic M: Developmental patterns of caspase-3, bax and bcl-2 proteins expression in the human spinal ganglia. J Mol Histol. 2008, 39: 339-349. 10.1007/s10735-008-9171-4.View ArticlePubMedGoogle Scholar
  20. Weibel ER: Stereological methods. Practical Methods for Biological Morphometry. 1979, Academic Press: LondonGoogle Scholar
  21. Petrovic D, Zorc M, Zorc-Pleskovic R, Vraspir-Porenta O: Morphometrical and stereological analysis of myocardial mast cells in myocarditis and dilated cardiomyopathy. Folia Biol (Praha). 1999, 45: 63-66.Google Scholar
  22. Zhang QY, Ge JB, Chen JZ, Zhu JH, Zhang LH, Lau CP, Tse HF: Mast cell contributes to cardiomyocyte apoptosis after coronary microembolization. J Histochem Cytochem. 2006, 54: 515-523. 10.1369/jhc.5A6804.2005.View ArticlePubMedGoogle Scholar
  23. Metcalfe DD, Boyce JA: Mast cell biology in evolution. J Allergy Clin Immunol. 2006, 117: 1227-1229. 10.1016/j.jaci.2006.03.031.View ArticlePubMedGoogle Scholar
  24. Kalesnikoff J, Galli SJ: New developments in mast cell biology. Nat Immunol. 2008, 9: 1215-1223. 10.1038/ni.f.216.PubMed CentralView ArticlePubMedGoogle Scholar
  25. Theoharides TC, Rozniecki JJ, Sahagian G, Jocobson S, Kempuraj D, Conti P, Kalogeromitros D: Impact of stress and mast cells on brain metastases. J Neuroimmunol. 2008, 205: 1-7. 10.1016/j.jneuroim.2008.09.014.View ArticlePubMedGoogle Scholar
  26. Han J, Zhang F, Xie J, Linhardt RJ, Hiebert LM: Changes in cultured endothelial cell glycosaminoglycans under hyperglycemic conditions and the effect of insulin and heparin. Cardiovasc Diabetol. 2009, 8: 46-10.1186/1475-2840-8-46.PubMed CentralView ArticlePubMedGoogle Scholar


© Pleskovič et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.